Sanofi Adds mRNA Specialist Tidal To Acquisition Spree

Focus Again On Cancer and Immunology

Sanofi has paid out $160m to add to its in-house expertise in mRNA and novel cell therapy technologies.

Sanofi building
Sanofi has made a string of acquisitions in the last 18 months, acquiring early and mid-stage companies and assets.

Sanofi has acquired Tidal Therapeutics, a privately owned company which aims to use its mRNA-based platform to create off-the-shelf cell therapies.

It has paid $160m upfront to acquire the Cambridge, MA-based firm and could add another $310m in milestone payments, depending...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip